Minerva Neurosciences | NERV - Loan Capital


Minerva Neurosciences reported $0 in Loan Capital for its fiscal quarter ending in September of 2024.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Adma Biologics USD 192.84M 745K Jun/2026
ALKERMES USD 1.48B 7.23M Jun/2026
Alterity Therapeutics Limited AUD 43.68K 59.53K Dec/2025
AstraZeneca USD 26.01B 46M Jun/2026
BioCryst Pharmaceuticals USD 395.4M 203K Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Cipla INR 3.82B 840.2M Mar/2026
Clal Biotechnology ILS 25.96M 18.48M Dec/2023
Compugen USD 0 0 Dec/2024
CSL USD 10.42B 273M Dec/2025
Eli Lilly USD 47.86B 8.49B Jun/2026
GlaxoSmithKline GBP 13.95B 65M Jun/2026
Grifols EUR 9.95B 722.93M Dec/2025
Halozyme Therapeutics USD 1.94B 1.79M Jun/2026
Ionis Pharmaceuticals USD 1.91B 6.62M Jun/2026
J&J USD 37.34B 183M Jun/2026
Merck USD 51.08B 4.41B Jun/2026
Minerva Neurosciences USD 0 86.58M Sep/2024
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 37.49B 42M Jun/2026
Novavax USD 246.3M 200K Dec/2025
Pfizer USD 60.5B 70M Jun/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sanofi EUR 14.65B 806M Jun/2026
Takeda JPY 4.42T 50.32B Jun/2026
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024